Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Two-way repeated measures ANOVA was used to assess the primary outcome of the change in PBAC scores.

Who Took Part

The abstract describes 2017 women taking part.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, women only.

The researchers conducted a randomised double-blind clinical trial between October 2016 and August 2017 in 100 women with HMB (defined as a pictorial blood assessment chart [PBAC] score >100) secondary to IUD use.

PBAC scores were collected in the three subsequent treatment cycles.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

The primary outcome was the difference in PBAC scores between the groups.

What Was Measured

The subject headings attached to it are Antifibrinolytic Agents, Flavonoids, Intrauterine Devices, Copper, Menorrhagia and Tranexamic Acid.

Author keywords: Contraception, IUD, heavy menstrual bleeding, intrauterine contraceptive device and micronised flavonoids.

What This Means in Plain Language

The paper is a randomized and double-blind study of Copper (Supplement) in 2017 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.